Status:
UNKNOWN
Validation of the Genetic Signature 354849 as a Prognostic Method
Lead Sponsor:
National Institute of Cancerología
Conditions:
Cervix Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This prospective study is focused on the validation of the genetic signature of 27 genes as a predictor of the response to concomitant chemotherapy treatment followed by brachytherapy in patients with...
Detailed Description
There are several studies of genes or genetic signatures associated with the response to treatment in cervical cancer, but so far it has not been possible to standardize the use of any biomarker or bi...
Eligibility Criteria
Inclusion
- Women over 18 years old
- Cervical Cancer at IB2-IVA FIGO´s clinical stages
- Histology: squamous, adenosquamous or adenocarcinoma
- No previous treatment
- No distance metastases, discard by PET/CT
- Functional State ECOG (Eastern Cooperative Oncology Group) 0-2
- Candidates to receive standard chemoradiotherapy treatment followed by brachytherapy
Exclusion
- Previous chemotherapeutic, surgical and/or radiotherapy treatment for female reproductive tract pathologies
- Previous invasive neoplasia (except non-melanoma skin cancer) unless there is complete remission of the disease of 3 years minimum.
- Previous systemic chemotherapy for the current cervical cancer.
Key Trial Info
Start Date :
September 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2024
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT04067882
Start Date
September 30 2019
End Date
May 30 2024
Last Update
November 14 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Cancerologia
Mexico City, Mexico City, Mexico, 14080
2
David Cantu de Leon
Mexico City, Tlalpan, Mexico, 14080